Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Hepatitis

  Free Subscription


Articles published in Gastroenterol Hepatol

Retrieve available abstracts of 48 articles:
HTML format



Single Articles


    January 2025
  1. LUIS CASTRO URDA J, Alvarez M, Cantero H, Ayala V, et al
    The efficiency of artificial intelligence for management and clinical decision-making in the identification of patients with undiagnosed HCV infection (Intelligen-C strategy).
    Gastroenterol Hepatol. 2025 Jan 18:502362. doi: 10.1016/j.gastrohep.2025.502362.
    PubMed     Abstract available


  2. FORNS X, Rodriguez M, Dominguez-Hernandez R, Cantero H, et al
    Cost analysis of hidden hepatitis D virus infection in Spain.
    Gastroenterol Hepatol. 2025 Jan 8:502337. doi: 10.1016/j.gastrohep.2025.502337.
    PubMed     Abstract available


    December 2024
  3. JIMENEZ-CASTILLO RA, Gonzalez-Martinez CE, Tovar-Bojorquez EM, Cortez-Hernandez CA, et al
    Prognostic value of relative adrenal insufficiency in patients with severe alcohol-associated hepatitis-a prospective clinical study.
    Gastroenterol Hepatol. 2024 Dec 12:502322. doi: 10.1016/j.gastrohep.2024.502322.
    PubMed     Abstract available


    November 2024
  4. LOPEZ DE LA CRUZ J, Gonzalvo MCA, Ortiz de Solorzano Reig M, Aguilar A, et al
    Acute cholestatic hepatitis secondary to idiopathic adult ductopenia.
    Gastroenterol Hepatol. 2024 Nov 14:502289. doi: 10.1016/j.gastrohep.2024.502289.
    PubMed    


  5. MIRALPEIX A, Ibanez P, Navarro V, Colomera P, et al
    Externalised nurse-led model for hepatitis C virus microelimination and impact of drug use profile.
    Gastroenterol Hepatol. 2024 Nov 13:502288. doi: 10.1016/j.gastrohep.2024.502288.
    PubMed     Abstract available


    October 2024
  6. LUO JX, Chen G, Hu XY, Yu C, et al
    Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis.
    Gastroenterol Hepatol. 2024 Oct 17:502276. doi: 10.1016/j.gastrohep.2024.502276.
    PubMed     Abstract available


    September 2024
  7. BUTI M, Calleja JL, Rodriguez MA, Dominguez-Hernandez R, et al
    Clinical and economic value of bulevirtide in the treatment of chronic hepatitis D.
    Gastroenterol Hepatol. 2024 Sep 7:502241. doi: 10.1016/j.gastrohep.2024.502241.
    PubMed     Abstract available


    June 2024
  8. BOLIS F, Cazzaniga G, Pagni F, Invernizzi P, et al
    The phenotypic landscape of primary biliary cholangitis and autoimmune hepatitis variants.
    Gastroenterol Hepatol. 2024 Jun 29:502225. doi: 10.1016/j.gastrohep.2024.502225.
    PubMed     Abstract available


  9. PARADA VAZQUEZ P, Perez-Cachafeiro S, Castineira Dominguez B, Gonzalez-Perez JM, et al
    Artificial intelligence-assisted identification and retrieval of chronic hepatitis C patients lost to follow-up in the health area of Pontevedra and O Salnes (Spain).
    Gastroenterol Hepatol. 2024 Jun 29:502226. doi: 10.1016/j.gastrohep.2024.502226.
    PubMed     Abstract available


  10. RODRIGUEZ-TAJES S, Palom A, Giraldez Gallego A, Moreno A, et al
    Characterizing Hepatitis Delta in Spain and the gaps in its management.
    Gastroenterol Hepatol. 2024 Jun 20:502222. doi: 10.1016/j.gastrohep.2024.502222.
    PubMed     Abstract available


    May 2024
  11. ESTEBAN R, Hernandez RD, Cantero H, Casado MA, et al
    Evaluacion del valor clinico y economico de sofosbuvir/velpatasvir (SOF/VEL) en pacientes con hepatitis C cronica en Espana durante los ultimos 5 anos.
    Gastroenterol Hepatol. 2024 May 7:502199. doi: 10.1016/j.gastrohep.2024.502199.
    PubMed     Abstract available


    February 2024
  12. JORQUERA F, Ledesma F, Ahumada A, Manzano ML, et al
    Clinical profile of Spanish hepatitis C virus-infected treatment-naive patients with compensated cirrhosis in the CREST study.
    Gastroenterol Hepatol. 2024 Feb 12:S0210-5705(24)00037.
    PubMed     Abstract available


  13. LIU Y, Chen S, Yu S, Wang J, et al
    LPS-TLR4 pathway exaggerates alcoholic hepatitis via provoking NETs formation.
    Gastroenterol Hepatol. 2024;47:158-169.
    PubMed     Abstract available


    December 2023
  14. CONTHE A, Ahumada A, Gallego Duran R, Marti-Aguado D, et al
    Current dilemmas in hepatitis virus C management. What should we do after achieving sustained virologic response?
    Gastroenterol Hepatol. 2023;46:826-829.
    PubMed    


  15. RIVEIRO-BARCIELA M, Roade L, Martinez-Camprecios J, Vidal-Gonzalez J, et al
    mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels).
    Gastroenterol Hepatol. 2023;46:764-773.
    PubMed     Abstract available


  16. ARZALLUS T, Izagirre A, Castiella A, Torrente S, et al
    Drug induced autoimmune hepatitis after turmeric intake.
    Gastroenterol Hepatol. 2023;46:805-806.
    PubMed    


    August 2023
  17. CALLEJA PANERO JL, de la Poza G, Hidalgo L, Aguilera Sancho-Tello MV, et al
    Patient journey of individuals tested for HCV in Spain: LiverTAI, a retrospective analysis of EHRs through natural language processing.
    Gastroenterol Hepatol. 2023;46:491-503.
    PubMed     Abstract available


    April 2023
  18. PEREZ-HERNANDEZ FJ, Morales-Arraez DE, Amaral-Gonzalez C, Gonzalez-Mendez Y, et al
    Asynchronous electronic consultation between primary care and specialized care proved effective for continuum of care for viraemic hepatitis C patients.
    Gastroenterol Hepatol. 2023;46:266-273.
    PubMed     Abstract available


  19. HUANG J, Liu Y, Liu Y
    Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis.
    Gastroenterol Hepatol. 2023;46:309-318.
    PubMed     Abstract available


    February 2023
  20. MARTINEZ RAMIREZ NM, Gonzalez Praetorius A, Martinez Benito Y, Garcia Rivera MV, et al
    Changes in the epidemiology of hepatitis A: Clinical and preventive implications.
    Gastroenterol Hepatol. 2023;46:116-123.
    PubMed     Abstract available


    January 2023
  21. FRAILE-LOPEZ M, Alvarez-Navascues C, Gonzalez-Dieguez ML, Cadahia V, et al
    Predictive models for hepatocellular carcinoma development after sustained virological response in advanced hepatitis C.
    Gastroenterol Hepatol. 2023 Jan 27:S0210-5705(23)00013.
    PubMed     Abstract available


  22. NEOKOSMIDIS G, Protopapas AA, Stogiannou D, Filippidis A, et al
    Cardiometabolic effects of direct-acting antivirals in patients with hepatitis C.
    Gastroenterol Hepatol. 2023;46:58-66.
    PubMed     Abstract available


  23. SHARKAWI FZE, El-Sherbiny M, Ali SAM, Nassif WMH, et al
    The potential value of plasma Circ-ITCH in hepatocellular carcinoma patients with current hepatitis C virus infection.
    Gastroenterol Hepatol. 2023;46:17-27.
    PubMed     Abstract available


    December 2022
  24. MARTINEZ-CAMPRECIOS J, Riveiro-Barciela M, Munoz-Gomez R, Londono MC, et al
    [Not Available].
    Gastroenterol Hepatol. 2022 Dec 27:S0210-5705(22)00313.
    PubMed    


    November 2022
  25. GARRIDO-ESTEPA M, Herruzo R, Flores-Herrera J
    Co-infections, comorbidities, and alcohol or other substances abuses in chronic hepatitis C-related hospitalisations in Spain.
    Gastroenterol Hepatol. 2022;45:677-689.
    PubMed     Abstract available


    October 2022
  26. CRESPO J, Cabezas J, Aguilera A, Berenguer M, et al
    Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction.
    Gastroenterol Hepatol. 2022 Oct 15. pii: S0210-5705(22)00235.
    PubMed    


  27. CUNHA-SILVA M, Torres LD, Fernandes MF, Secundo TML, et al
    Changes in indications for outpatient percutaneous liver biopsy over 5 years: from hepatitis C to fatty liver disease.
    Gastroenterol Hepatol. 2022;45:579-584.
    PubMed     Abstract available


    August 2022
  28. LAVIN AC, Cabezas J, Crespo J
    Letter to the editor in response to the recently published article "Roncero C, Buch B, Martin-Sanchez AM, et al. Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis. Gastroenterol Hepato
    Gastroenterol Hepatol. 2022 Aug 11. pii: S0210-5705(22)00183.
    PubMed    


    June 2022
  29. RONCERO C, Buch B, Martin-Sanchez AM, Alvarez-Navares AI, et al
    Prevalence of hepatitis C virus infection in patients with chronic mental disorders: the relevance of dual diagnosis.
    Gastroenterol Hepatol. 2022 Jun 30. pii: S0210-5705(22)00172.
    PubMed     Abstract available


  30. GUTIERREZ-ROJAS L, de la Gandara Martin JJ, Garcia Buey L, Uriz Otano JI, et al
    Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: results of a literature review.
    Gastroenterol Hepatol. 2022 Jun 16. pii: S0210-5705(22)00164.
    PubMed     Abstract available


    May 2022
  31. ANDRES L, Badia E, Fernandez C, Puebla A, et al
    AUTOIMMUNE HEPATITIS. ANOTHER CONSEQUENCE OF COVID-19?
    Gastroenterol Hepatol. 2022 May 13. pii: S0210-5705(22)00150.
    PubMed    


  32. CHEN M, Wu Z, Du Z, Sun S, et al
    Diagnostic accuracy of red blood cell distribution width to platelet ratio for predicting liver fibrosis in patients with chronic hepatitis B: A meta-analysis.
    Gastroenterol Hepatol. 2022;45:361-372.
    PubMed     Abstract available


    April 2022
  33. TORRENTE S, Castiella A, Garmendia M, Zapata E, et al
    Probable autoimmune hepatitis reactivated after COVID-19 vaccination.
    Gastroenterol Hepatol. 2022;45 Suppl 1:115-116.
    PubMed    


  34. MACIA-RODRIGUEZ C, Santome Couto L, Fernandez Villaverde A, Romero Reinoso C, et al
    Mycophenolate mofetil as a treatment of severe steroid-resistant immune-related hepatitis.
    Gastroenterol Hepatol. 2022;45 Suppl 1:32-36.
    PubMed    


    March 2022
  35. NUNEZ F P, Quera R, Bay C, Thomson P, et al
    Fecal microbiota transplant, its usefulness beyond Clostridioides difficile in gastrointestinal diseases.
    Gastroenterol Hepatol. 2022;45:223-230.
    PubMed     Abstract available


  36. PEREZ JIMENEZ RD, Granados Monzon R, Hernandez Febles M, Pena Lopez MJ, et al
    Acute hepatitis due to the hepatitisC virus: Where are the transmission occurring?
    Gastroenterol Hepatol. 2022;45:192-197.
    PubMed     Abstract available


    February 2022
  37. ARANDA EB, Marcos CF, Maestu AP, Marin VG, et al
    EVOLUTION OF HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS CURED WITH DIRECT-ACTING ANTIVIRALS. LONG-TERM FOLLOW-UP.
    Gastroenterol Hepatol. 2022 Feb 18. pii: S0210-5705(22)00064.
    PubMed     Abstract available


  38. RASHIDI A, Sedaghat F, Nejat A, Azarpira N, et al
    Immunity to hepatitis A virus in liver transplant recipients: A population-based study in Iran.
    Gastroenterol Hepatol. 2022;45:99-105.
    PubMed     Abstract available


  39. ROCHA HC, Vilela EG
    Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases.
    Gastroenterol Hepatol. 2022;45:83-90.
    PubMed     Abstract available


    December 2021
  40. OLIVAS I, Cobreros M, Londono MC, Diaz-Gonzalez A, et al
    Budesonide in the first line treatment of patients with autoimmune hepatitis.
    Gastroenterol Hepatol. 2021 Dec 16. pii: S0210-5705(21)00319.
    PubMed     Abstract available


    October 2021
  41. CALVET X, Carpio D, Rodriguez-Lago I, Garcia-Vicuna R, et al
    Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
    Gastroenterol Hepatol. 2021;44:587-598.
    PubMed     Abstract available


    September 2021
  42. GARCIA-FRAILE LJ, Garcia-Buey L, Cerezo CA, Sanz JS, et al
    ENGLISH: Evolution of HCV associated Porphyria Cutanea Tarda after HCV Sustained Virologic Response by Direct Acting Antivirals.
    Gastroenterol Hepatol. 2021 Sep 22. pii: S0210-5705(21)00248.
    PubMed     Abstract available


  43. DE CANETE CAMACHO JCF, Martinez AM, Mena MAG, Maria Moreno Planas J, et al
    Influence of psychiatric disorders and opioid substitution therapy on hepatitis c treatment with direct-acting antivirals in people who inject drugs.
    Gastroenterol Hepatol. 2021 Sep 17. pii: S0210-5705(21)00251.
    PubMed     Abstract available


  44. CAMARERO JG, Aranda EB, Castro RQ, Chumillas RMS, et al
    Hepatitis B And C Screening In Hospitalized Patients With Sars-Cov-2 Infection.
    Gastroenterol Hepatol. 2021 Sep 8. pii: S0210-5705(21)00250.
    PubMed     Abstract available


    June 2021
  45. TURNES J, Rincon D, Calleja JL, Delgado MB, et al
    Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naive non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Gastroenterol Hepatol. 2021 Jun 12. pii: S0210-5705(21)00198.
    PubMed     Abstract available


    May 2021
  46. REYGOSA C, Arraez DM, Hernandez-Bustabad A, Baute LM, et al
    Hepatitis C-Treated Patients As A Potential Source For Referral Of New Cases.
    Gastroenterol Hepatol. 2021 May 20. pii: S0210-5705(21)00148.
    PubMed     Abstract available


    April 2021
  47. BUSTA NISTAL MR, Garcia Sanchez MC, Mora Cuadrado N, Dura Gil M, et al
    Cholestatic hepatitis as a presentation of secondary syphilis.
    Gastroenterol Hepatol. 2021 Apr 16. pii: S0210-5705(21)00117.
    PubMed    


  48. COSTA CA, Garcia JLR, Gandia MAR, Martos RF, et al
    FULMINANT LIVER FAILURE DUE TO HEPATITIS B REACTIVATION DURING THE COVID-19 PANDEMIC.
    Gastroenterol Hepatol. 2021 Apr 13. pii: S0210-5705(21)00118.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.